CSL Behring LLC

CSL Behring LLC is a global biotechnology company specializing in plasma-derived and recombinant biotherapies for rare and serious diseases. The company manufactures and distributes immunoglobulins, clotting factor concentrates for hemophilia and bleeding disorders, therapies for immunodeficiencies, treatments for hereditary angioedema, and Alpha-1 antitrypsin deficiency products. As part of the larger CSL Limited group (founded 1916), CSL Behring operates manufacturing and distribution networks across over 100 countries, with significant recent investment ($1.5 billion) in U.S. plasma-based medicine manufacturing. The company emphasizes quality management, regulatory compliance, and innovation in cell culture reagents and plasma collection infrastructure. CSL's broader portfolio includes CSL Seqirus (vaccines, including influenza and pandemic preparedness), CSL Vifor (iron deficiency and nephrology/dialysis therapies), and CSL Plasma (plasma source plasma collection). With over 25,000 employees globally, the organization focuses on delivering life-saving therapies for bleeding disorders, immune system conditions, and chronic kidney disease.